Your data on MRCVSonline
The nature of the services provided by Vision Media means that we might obtain certain information about you.
Please read our Data Protection and Privacy Policy for details.

In addition, (with your consent) some parts of our website may store a 'cookie' in your browser for the purposes of
functionality or performance monitoring.
Click here to manage your settings.
If you would like to forward this story on to a friend, simply fill in the form below and click send.

Your friend's email:
Your email:
Your name:
 
 
Send Cancel

Professor calls for better clinical trials of antivirals
Cats suffering from FIV and FeLV require special management and care.

Review looks at antiviral use in retrovirus-infected cats

A leading professor in small animal medicine is calling for better clinical trials of antivirals following publication of a review into their use in retrovirus-infected cats.

Professor Katrin Hartmann, head of the clinic of small animal medicine at the LMU University of Munich, Germany, says that more well-designed clinical trials would improve judgement on treatment efficacy and side effects.

Antiviral chemotherapy is of increasing interest in veterinary medicine, but is still not commonly used.  The review, published in the Journal of Feline Medicine and Surgery, examines current literature on antiviral chemotherapy in retrovirus-infected cats, focusing on drugs that are currently available on the market, and therefore could potentially be used in cats.

Concluding the review, Professor Hartmann writes: 'Unfortunately, the level of efficacy of antiviral chemotherapy is often poor and the duration of treatments used in clinical trials is often inappropriate for infections with such long clinical courses.

'Additionally, the degree of generalisability between experimental infections in cats kept under laboratory conditions and pet cats infected with field strains is unknown.
Therefore, it is very important that more well-designed double-blind, placebo-controlled trials using antivirals in naturally retrovirus-infected cats are undertaken to allow judgement on treatment efficacy and side effects of different antiviral compounds.'

Feline immunodeficiency virus (FIV) and feline leukaemia virus (FeLV) are among the most common infections affecting cats worldwide, but differ in their potential to cause disease. 
Cats suffering from FIV and FeLV require special management and care and, provided they receive this, can live for many years in good health.

In more severe cases, the advice is to consider incorporating antivirals into the treatment regime. Most antivirals used in cats are licensed for humans and are specifically intended for treatment of human immunodeficiency virus (HIV), based on the rationale that FIV and HIV are closely related.

FeLV is not as closely related to HIV, with the result that the available drugs have mostly been found to be less effective against this retrovirus.

 

Become a member or log in to add this story to your CPD history

Practices urged to audit neutering data

News Story 1
 RCVS Knowledge has called on vet practices to audit their post-operative neutering outcomes.

It follows the release of the 2024 NASAN benchmarking report, which collates data from neutering procedures performed on dogs, cats and rabbits.

The benchmarking report enables practices in the UK and Ireland to compare their post-operative outcomes to the national average. This includes the rate of patients lost to follow-up, which in 2024 increased to 23 per cent.

Anyone from the practice can submit the data using a free template. The deadline for next report is February 2026.

Visit the RCVS Knowledge website to complete an audit. 

Click here for more...
News Shorts
UK's BSE risk status downgraded

The WOAH has downgraded the UK's international risk status for BSE to 'negligible'.

Defra says that the UK's improved risk status recognises the reputation for having the highest standards for biosecurity. It adds that it demonstrates decades of rigorous animal control.

Outbreaks of Bovine Spongiform Encephalopathy, also known as mad cow disease, have previously resulted in bans on Britain's beef exports.

The UK's new status could lead to expanded trade and better confidence in British beef.

Christine Middlemiss, the UK's chief veterinary officer, said: "WOAH's recognition of the UK as negligible risk for BSE is a significant milestone and is a testament to the UK's strong biosecurity measures and the hard work and vigilance of farmers and livestock keepers across the country who have all played their part in managing the spread of this disease.